Related Experiment Video
Updated: Jul 4, 2026

Production of Disulfide-stabilized Transmembrane Peptide Complexes for Structural Studies
Published on: March 6, 2013
NOV-002, a mimetic of glutathione disulfide
Danyelle M Townsend1, Christopher J Pazoles, Kenneth D Tew
1Medical University of South Carolina, Department of Pharmaceutical Sciences, 173 Ashley Avenue, PO Box 250505, Charleston, SC 29425, USA.
Background:
Oxidative signaling to modulate redox-sensitive cell functions is a heretofore unexploited approach to developing new drugs for poorly treated oncology indications, where current therapies are often only palliative and accompanied by severe toxicities.
Objective:
Clinical and non-clinical findings with NOV-002 (a mimetic of glutathione disulfide that represents such an approach) are reviewed and evaluated.
Methods:
Published data on NOV-002 along with unpublished information from the drug's sponsor were reviewed. Literature analysis also focused on protein S-glutathionylation as a regulatory mechanism, particularly in relation to cell signaling, proliferation and cytoskeletal architecture.
Results/Conclusion:
NOV-002 is a mechanistically novel agent with potential for ameliorating hematologic toxicity and enhancing efficacy when used in combination with standard chemotherapy to treat cancer patients.
Insights
NOV-002, a novel drug mimicking glutathione disulfide, shows promise in cancer treatment. It may reduce chemotherapy side effects and improve treatment effectiveness in oncology patients.
Area of Science:
- Biochemistry
- Oncology
- Pharmacology
Background:
- Oxidative signaling is an underutilized strategy for novel cancer drug development.
- Current oncology treatments often provide palliative care with significant toxicities.
Purpose of the Study:
- To review and evaluate clinical and non-clinical findings for NOV-002.
- NOV-002 is a mimetic of glutathione disulfide.
Main Methods:
- Analysis of published data and unpublished sponsor information on NOV-002.
- Literature review on protein S-glutathionylation in cell signaling, proliferation, and cytoskeletal architecture.
Main Results:
- NOV-002 is a mechanistically novel agent.
- Potential to mitigate hematologic toxicity associated with chemotherapy.
- Potential to enhance efficacy when combined with standard chemotherapy.
Conclusions:
- NOV-002 demonstrates potential as a supportive agent in cancer therapy.
- Further investigation into NOV-002's role in combination cancer treatment is warranted.
More Related Videos
03:35Rapid Quantification of Oxidized and Reduced Forms of Glutathione Using Ortho -phthalaldehyde in Cultured Mammalian Cells In Vitro
Published on: June 28, 2024
07:47Live Imaging of the Mitochondrial Glutathione Redox State in Primary Neurons using a Ratiometric Indicator
Published on: October 20, 2021
Related Concept Videos
Phase II Reactions: Glutathione Conjugation and Mercapturic Acid Formation
Several distinctive characteristics distinguish glutathione conjugation from other phase II...
Preparation and Reactions of Thiols
Sulfur Assimilation
Preparation and Reactions of Sulfides
Structure and Nomenclature of Thiols and Sulfides